Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma

Hepatology International - 2011
Satoshi Ogasawara1, Fumihiko Kanai1, Shuntaro Obi2, Shinpei Sato2, Taketo Yamaguchi3, Ryosaku Azemoto4, Hideaki Mizumoto5, Youhei Koushima6, Naoki Morimoto7, Nobuto Hirata8, Takeshi Toriyabe1, Yusuke Shinozaki1, Yoshihiko Ooka1, Rintaro Mikata1, Tetsuhiro Chiba1, Shinichiro Okabe1, Fumio Imazeki1, Masaharu Yoshikawa1, Osamu Yokosuka1
1Department of Medicine and Clinical Oncology, Graduate School of Medicine, University of Chiba, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan
2Department of Gastroenterology and Hepatology, Kyoundo Hospital, 1-8 Kandasurugadai, Chiyoda-ku, 101-0062, Tokyo, Japan
3Department of Gastroenterology, Chiba Cancer Centre, 666-2 Nitonacho, Chuo-ku, 260-8717, Chiba, Japan
4Department of Gastroenterology, Kimitsu-Chuo Hospital, 1010 Sakurai, 292-8535, Kisarazu, Japan
5Department of Gastroenterology, Funabashi Municipal Medical Centre, 1-21-1 Kanasugi, 273-8588, Funabashi, Japan
6Department of Gastroenterology, Saitama Red Cross Hospital, 8-3-33 Kamiochiai, Chuo-Ku, 333-8533, Saitama, Japan
7Department of Gastroenterology, Shimotsuga-Sogo Hospital, 5-32 Fujimi, 328-8505, Tochigi, Japan
8Department of Gastroenterology, Kameda Medical Centre, 929 Higashicho, 296-0042, Kamogawa, Japan

Tóm tắt

Từ khóa


Tài liệu tham khảo

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74–108

Shiratori Y, Shiina S, Imamura M, Kato N, Kanai F, Okudaira T, Teratani T, Tohgo G, Toda N, Ohashi M, et al. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan. Part 1. Hepatology 1995;22(4):1027–1033

Okuda H. Hepatocellular carcinoma development in cirrhosis. Best Pract Res Clin Gastroenterol 2007;21(1):161–173

Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362(9399):1907–17

McGlynn KA, Tsao L, Hsing AW, Devesa SS, Fraumeni JF Jr. International trends and patterns of primary liver cancer. Int J Cancer 2001;94(2):290–296

Umemura T, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. Hepatol Res 2007;37(Suppl 2):S95–S100

El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340(10):745–750

Ryu M, Shimamura Y, Kinoshita T, Konishi M, Kawano N, Iwasaki M, Furuse J, Yoshino M, Moriyama N, Sugita M. Therapeutic results of resection, transcatheter arterial embolization and percutaneous transhepatic ethanol injection in 3225 patients with hepatocellular carcinoma: A retrospective multicentre study. Jpn J Clin Oncol 1997;27(4):251–257

Okuda K, Mitchell DG, Itai Y. In Hepatobiliary Disease Primary Malignant Tumors of the Liver. London: Blackwell; 2001. 343–389

Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35(3):421–430

Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359(9319):1734–1739

Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, Yamaoka Y. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006;131(2):461–469

Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64(19):7099–7109

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378–390

Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10(1):25–34

Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008;99(1):159–165

Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24(26):4293–4300

Yuen MF, Hou JL, Chutaputti A. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 2009;24(3):346–353

Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 2007;37(10):755–762

Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 2008;9(2):117–123

Ozenne V, Paradis V, Pernot S, Castelnau C, Vullierme MP, Bouattour M, Valla D, Farges O, Degos F. Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol 2010;22(9):1106–1110

Pinter M, Sieghart W, Graziadei I, Vogel W, Maieron A, Konigsberg R, Weissmann A, Kornek G, Plank C, Peck-Radosavljevic M. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 2009;14(1):70–76

Thông tin
Thông tin xuất bản

Hepatology International

Thông tin tác giả